PDT Partners LLC Has $1.63 Million Stock Holdings in GoodRx Holdings, Inc. $GDRX

Key Points

• PDT Partners LLC significantly increased its stake in GoodRx Holdings by 1,351.3% during the first quarter, owning a total of 370,219 shares valued at $1.63 million.
• Several large institutional investors, including Vanguard Group and Dimensional Fund Advisors, also increased their holdings in GoodRx, with 63.77% of the stock owned by institutional investors overall.
• Analysts have mixed sentiments on GoodRx, with ratings ranging from "strong-buy" to "hold", and a current average target price of $5.80 per share.

PDT Partners LLC grew its stake in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 1,351.3% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 370,219 shares of the company's stock after purchasing an additional 344,709 shares during the quarter. PDT Partners LLC owned approximately 0.10% of GoodRx worth $1,633,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of GDRX. Envestnet Asset Management Inc. bought a new stake in GoodRx during the 4th quarter worth approximately $84,000. Barclays PLC lifted its holdings in shares of GoodRx by 18.4% during the fourth quarter. Barclays PLC now owns 165,928 shares of the company's stock valued at $772,000 after purchasing an additional 25,815 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of GoodRx by 22.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company's stock worth $9,264,000 after purchasing an additional 369,553 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in GoodRx by 28.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 255,192 shares of the company's stock valued at $1,188,000 after purchasing an additional 56,522 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in GoodRx by 13.5% in the 4th quarter. Northern Trust Corp now owns 421,810 shares of the company's stock worth $1,961,000 after purchasing an additional 50,256 shares in the last quarter. Institutional investors own 63.77% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on GDRX. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a $6.00 target price on shares of GoodRx in a research note on Monday, August 11th. UBS Group dropped their price objective on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Finally, Raymond James Financial lowered GoodRx from a "strong-buy" rating to an "outperform" rating in a research report on Friday, August 8th. Five analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, GoodRx presently has a consensus rating of "Hold" and a consensus price target of $5.80.

GoodRx Stock Performance

Shares of NASDAQ GDRX traded up $0.12 during midday trading on Monday, reaching $4.12. 1,482,479 shares of the company were exchanged, compared to its average volume of 2,008,236. The stock has a market cap of $1.43 billion, a P/E ratio of 41.15, a PEG ratio of 1.74 and a beta of 1.23. The stock has a fifty day simple moving average of $4.51 and a 200 day simple moving average of $4.45. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.75. GoodRx Holdings, Inc. has a 1 year low of $3.31 and a 1 year high of $7.90.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). The company had revenue of $203.07 million for the quarter, compared to analysts' expectations of $205.72 million. GoodRx had a return on equity of 8.86% and a net margin of 4.33%.GoodRx's revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.08 earnings per share. On average, research analysts forecast that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current fiscal year.

Insider Activity at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $4.80, for a total transaction of $51,249.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 4.17% of the company's stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.